GSK Aftermath: Industry Grapples With Compliance Issues
This article was originally published in PharmAsia News
Executive Summary
Despite wide anticipation, the GSK China bribe ruling still surprised many. The pharma industry is now pondering its next steps to meet a rising bar and the soaring costs of compliance, in addition to coping with a continuously challenging business environment, RDPAC tells PharmAsia News in an interview.